Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

UK health authorities are investigating pancreatitis cases linked to weight-loss drugs like Ozempic and Mounjaro. We spoke to ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...